Effects of PPAR-γ agonists on oral cancer cell lines: Potential horizons for chemopreventives and adjunctive therapies

Jeffrey A. Hall, Mark Rusten, Raed D. Abughazaleh, Beverly Wuertz, Vannesa Souksavong, Paul Escher, Frank Ondrey

Research output: Contribution to journalArticle

Abstract

Background: Peroxisome proliferator-activated receptor-gamma (PPAR-γ) activators have anti-cancer effects. Our objective was to determine the effect of PPAR-γ ligands 15-deoxy-D12,14-Prostaglandin J2 (15-PGJ2) and ciglitazone on proliferation, apoptosis, and NF-κB in human oral squamous cell carcinoma cell lines. Methods: NA and CA9-22 cells were treated in vitro with 15-PGJ2 and ciglitazone. Proliferation was measured by MTT colorimetric assay and cell cycle analysis performed via flow cytometry, apoptosis by caspase-3 colorimetric assay and poly-(ADP-ribose) polymerase cleavage on Western blot, and NF-κB activation by luciferase assays. Results: MTT assays demonstrated dose-dependent decreases after 15-PGJ2 treatment in both cell lines, and S-phase cell cycle arrest was also demonstrated. NF-κB luciferase reporter gene activity decreased seven- and eightfold in NA and CA9-22 cells, respectively. Caspase-3 activity increased two- and eightfold in NA and CA9-22 cells, respectively. Conclusions: Our results suggest these agents, in addition to activating PPAR-γ, can downregulate NF-κB and potentiate apoptosis in oral cancer cells.

Original languageEnglish (US)
Pages (from-to)2542-2554
Number of pages13
JournalHead and Neck
Volume42
Issue number9
DOIs
StatePublished - Sep 1 2020

Keywords

  • 15-deoxy-D-prostaglandin J (15-PGJ)
  • Ciglitazone
  • NF-κB
  • PPAR-γ
  • squamous cell carcinoma

PubMed: MeSH publication types

  • Journal Article

Fingerprint Dive into the research topics of 'Effects of PPAR-γ agonists on oral cancer cell lines: Potential horizons for chemopreventives and adjunctive therapies'. Together they form a unique fingerprint.

  • Cite this